Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Leuk Res. 2013 Oct;37(10):1208-12. doi: 10.1016/j.leukres.2013.07.015. Epub 2013 Aug 5.
Elevated absolute monocyte counts (AMCs) have been reported to indicate poor prognosis for patients with lymphoproliferative disease, including those with follicular lymphoma (FL) receiving various treatments. We evaluated the prognostic impact of AMC in 150 consecutive FL patients who received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Progression-free survival (PFS) did not differ significantly according to the AMC level. Univariate and multivariate analyses did not indicate a prognostic significance of AMC for PFS. Thus, the AMC is not a prognostic factor for FL patients treated with R-CHOP. However, immunochemotherapy might influence the prognostic impact of AMC.
已有研究报道，绝对单核细胞计数（AMC）升高与淋巴增殖性疾病患者，包括接受各种治疗的滤泡性淋巴瘤（FL）患者的不良预后相关。我们评估了 150 例连续接受利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗的 FL 患者的 AMC 对预后的影响。根据 AMC 水平，无进展生存期（PFS）无显著差异。单因素和多因素分析均表明 AMC 对 PFS 无预后意义。因此，AMC 不是接受 R-CHOP 治疗的 FL 患者的预后因素。然而，免疫化学疗法可能会影响 AMC 的预后影响。
